GlobeNewswire Inc.··NaImmix Biopharma's CAR-T Therapy Achieves Rare 95% Complete Response in Amyloidosis Trial
Immix Biopharma reports 95% complete response rate with zero relapses in CAR-T therapy trial for relapsed/refractory AL amyloidosis, planning Phase 3 initiation and 2027 BLA submission.
IMMXclinical trialBreakthrough Therapy Designation